Here’s how Mesoblast Ltd (MESO) stock price rocketed in the Pre-market hours

Mesoblast Ltd (MESO) stock surged in the pre-market session as the company skyrocketed +99.77% at 17,72 after the global leader in allogeneic cellular products for inflammation diseases, announced UPBEAT additional results from the DREAM-HF study, an examination of 537 patients with chronic heart failure who were not eligible for rexlemestrocel-L or control sham.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Various clinical studies have demonstrated substantial and durable reductions in heart attacks, strokes, and cardiac deaths following a single dose of rexlemestrocel-L.

This significant improvement may be the first breakthrough in improving outcomes among chronic heart failure patients. These results suggest the New York Heart Association (NYHA) class II HFrEF patients as the best targets for commercialization and registration of rexlemestrocel-L in this large market of heart failure patients.


Please enter your comment!
Please enter your name here